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Abstract
The CHFR protein comprises fork head associated- (FHA) and RING-finger (RF) domain and is frequently downregulated in
human colon and gastric cancers up to 50%. The loss of CHFR mRNA expression is a consequence of promoter methylation,
suggesting a tumor suppressor role for this gene in gastrointestinal carcinogenesis. In terms of the biological functions of
CHFR, it has been shown to activate cell cycle checkpoint when cells are treated with microtubule depolymerizing agents.
Furthermore, CHFR was reported to have E3 ligase activity and promote ubiquitination and degradation of oncogenic
proteins such as Aurora A and polo-like kinase 1. However, molecular pathways involved in the tumor suppressive function
of CHFR are not yet clear since the two established roles of this protein are likely to inhibit cell growth. In this study, we have
identified that the FHA domain of CHFR protein is critical for growth suppressive properties, whereas the RF and cysteine
rich domains (Cys) are not required for this function. In contrast, the RF and Cys domains are essential for E3 ligase activity of
CHFR. By the use of a cell cycle checkpoint assay, we also confirmed that the FHA domain of CHFR plays an important role in
initiating a cell cycle arrest at G2/M, indicating a functional link exists between the anti-proliferative effects and checkpoint
function of this tumor suppressor protein via this domain. Collectively, our data show that the checkpoint function of the
FHA domain of CHFR is a core component of anti-proliferative properties against the gastrointestinal carcinogenesis.
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Introduction
CHFR (Checkpoint protein with Forkhead associated and Ring
finger domain) was first isolated by a homology screening of EST
cDNA clones harboring an FHA domain [1]. The CHFR protein
is characterized by the existence of two domain structures that are
well conserved across different species, namely the FHA and
RING finger domains (RF) [1]. CHFR is in fact the only protein in
vertebrates that contains both of these functional domains.
The FHA domain of CHFR has been reported to arrest the cell
cycle under mitotic stress conditions caused by microtubule
depolymerizing agents such as nocodazole, and this moiety thus
confers a mitotic checkpoint function upon this protein [2–6]. In
terms of the mechanisms underlying this checkpoint function,
CHFR has been shown to exclude Cyclin B1 from the nucleus,
resulting in the arrest of the cell cycle at around the G2 phase [7].
Other checkpoint regulators with an FHA domain, such as CHK2
and NBS1, have also shown similar features and arrest the cell
cycle in response to DNA damage and replication blocks [8,9].
These checkpoint proteins containing FHA domain have been
shown to function as tumor suppressors, although the detailed
molecular mechanisms are not yet fully elucidated. For example,
the inactivation of the CHK2 and NBS1 proteins increases the
predisposition of cells to cancer development [8,10–14]. The
functional inactivation of CHFR due to promoter methylation and
the consequent loss of mRNA expression is frequently observed in
human colon and gastric cancers [4,15–19], suggesting its possible
role also as a tumor suppressor. The functional loss of these
checkpoint proteins is likely to disrupt the cell cycle arrest response
to cellular stress, thus leading to the accumulation of mutations
and replication errors in the genome, a prerequisite for malignant
transformation.
The RING-finger domain is a characteristic feature of the E3
ligase proteins [1] and is thought to determine the substrate
specificity for ubiquitination reactions. As an example, the RING-
finger protein cdc20 is known to serve as an E3 ligase for the
anaphase promoting complex/cyclosome (APC/C) [20], and
Cyclin B is also one of its substrates [20]. Cyclin B proteins that
have been polyubiquitinated by cdc20 are rapidly transferred to
the proteasome and degraded. CHFR was shown to play a role as
E3 ligase for the polyubiqutination of Aurora A and Polo-like-
kinase 1 [21,22], possibly resulting in the degradation of these
proteins. In fact, mouse embryonic fibroblasts (MEF) derived from
Chfr knockout mice show elevated protein levels of Aurora A and
display chromosome abnormalities [21]. The inactivation of
CHFR may thus cause the up-regulation of these proteins, which
are known mitotic kinases and are frequently observed to be
overexpressed in various types of human malignant tumors, such
as bladder and colon cancers [23,24]. Elevated levels of Aurora A
and Plk1 are known to induce abnormal mitotic cell division and
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[25,26]. The functional loss of CHFR could therefore result in
the accumulation of oncogenic proteins (Aurora A and Plk1) and
induce genomic instability.
To date, two possible molecular pathways have been considered
as the mechanisms underlying the tumor suppressor function of
CHFR. These are the checkpoint regulation and E3 ligase
functions of this protein. However, it is difficult to draw any
conclusions from the findings of previous studies about which of
these roles is the most critical for growth suppression, since
functional analyses of the checkpoint and E3 ligase activity of
CHFR have only been performed independently of each other
thus far [1,22,27–29]. We initially focused on the E3 ligase activity
as a possible pathway for the growth suppressive properties of
CHFR as our previous data have shown that degradation by the
proteasome is the major rate limiting step in the control of the
Aurora A protein levels [30]. If the E3 ligase activity of CHFR is
more important for growth suppression, as we initially expected,
the core region of this tumor suppressor that is required for its
anti-proliferative effects was anticipated to be the RF domain.
In our current study, we have investigated the molecular
pathways underlying the growth suppressive functions of CHFR
by utilizing genetic rescue experiments with colon cancer cell lines
in which endogenous CHFR is epigenetically inactivated.
Materials and Methods
CHFR plasmids
A cDNA fragment of human CHFR (NIH Mammalian Gene
Collection ID: 19963) was obtained by RT-PCR from a human
pancreatic cancer cell line (Panc1) based on a method described
previously [30]. A hemagglutinin (HA) protein tag sequence was
then introduced at the amino terminus of this recombinant CHFR
product and a Kozak sequence was inserted just upstream of
the start codon of the HA protein tag. Mutant cDNA fragments
were created using the quick change PCR kit (Stratagene) with
slight modifications [31]. To generate a DFHA mutant, a CHFR
cDNA fragment was generated that lacked the 110 amino acids
between the original start methionine and the end of the FHA
domain (MERPEEGKQS-EPEHNVAYLYESLS). An RF mutant
(DRF) was similarly designed by generating a truncated CHFR
cDNA lacking this 48 amino acid domain (CIICQDLLHD-
TCRCPVERICK). A TGA stop codon was inserted into the
CHFR cDNA to construct the cysteine rich domain mutant (DCys)
by producing a protein product lacking the 190 amino acids of this
region (VCPLQGSHAL-HICEQTRFKN).
Each cDNA was subcloned into the EcoRV site of pBluescript
SKII+ (Stratagene) by blunt end ligation, and the resulting
constructs were validated in a cycle sequencing reaction with an
ABI 310 genetic analyzer (Applied Biosystems). Both the wild-type
and mutant CHFR cDNA fragments were also subcloned into an
LXIN retrovirus vector (Clontech), the pcDNA 3.1+ plasmid
(Invitrogen), and an IRES2-EGFP bicistronic expression vector
(Clontech). The retrovirus vectors were used in colony formation
assays, whereas the pcDNA 3.1+ vectors were used in an in vivo
ubiquitination assay and also in the cellular localization exper-
iments. The bicistronic vectors (IRES2-EGFP) were employed in
the checkpoint analyses.
Stable and transient expression of wild-type and mutant
CHFR proteins in cultured cells
HCT116, RKO and HeLa cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM; Sigma) supplemented with
10% fetal bovine serum (FBS), penicillin (100U/ml), and
streptomycin (50U/ml), at 37uC and 5% CO2. A PT67 retrovirus
packaging cell line was obtained from Clontech, and maintained
in DMEM with 10% FBS. Cells were maintained in an
exponential growth phase prior to use.
Retroviral constructs harboring wild-type or mutant human
CHFR cDNAs, were introduced into PT67 cells (Clontech) for
packaging using the lipofection method (Fugene 6, Roche). The
LXIN retroviral vector contains a neomycin cassette, and cells that
stably produced recombinant retroviruses were selected after two
weeks of culture in the presence of 1 mg/ml G418. The retroviral
supernatants were diluted 1:2 with normal DMEM containing
10% FBS and exposed to HCT116 or RKO cells with 400 mg/ml
of polybrane infection enhancer. Infected cells were further
selected with 1 mg/ml G418 for two weeks. To avoid cloning
bias, the whole cell population that showed resistance to G418 was
used in each experiment. For transient expression experiments,
cells at 70% confluency were transfected with 2.5 mg of the
indicated plasmids using the lipofection method (Lipofectamine
2000, Invitrogen), according to the manufacturer’s protocol.
Colony formation assay
1610
6 HCT116, RKO or HeLa cells were infected with
aliquots of LXIN retroviral supernatants from the PT67 packaging
cells for 48 h. When the infected cells reached confluence, they
were trypsinized and resuspended in 10 ml of DMEM supple-
mented with 10% FBS. 10 ml (HCT116) or 100 ml (RKO or
HeLa) aliquots of these cell suspensions were then seeded into
100 mm culture dishes (Nunc, 150350), and grown in G418
selection for two weeks as described above. G418-resistant colonies
were subsequently fixed in 4% paraformaldehyde in phosphate
buffered saline (PBS), and stained with hematoxilin. Images of the
stained dishes were captured using a high-resolution digital camera
with a macro lens (Fuji Film), and the numbers of colonies were
determined in each image using NIH image software. The average
colony numbers were then calculated from five dishes in three
independent experiments. Statistical significance was evaluated
with the Wilcoxon-Mann-Whitney U-test.
Measurement of the retrovirus titers of the producer cells
The conditioned medium of the producer cells was diluted 1:50
with distilled water and subjected to reverse transcription. The
copy number of the resulting retroviral cDNA was measured by
real-time PCR with a Retrovirus titer set (Takara Bio, Kyoto,
Japan). The average retrovirus copy number of per ml was
determined from five independent reactions. The reverse tran-
scriptase and real-time PCR reactions were performed according
to the manufacturer’s instructions.
Western blot analysis
Cells were lysed in ice-cold HIPS buffer (50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1% Triton X-100) [30] and the resulting
whole cell lysates were subjected to 10% SDS-PAGE. The
separated proteins were then transferred to polyvinylidene
difluoride (PVDF) membranes (Immobilon P, Millipore). After
blocking with 7% non-fat dry milk-Tris buffered saline and 0.1%
Tween 20 (TBST), the membranes were probed with anti-HA
(High affinity HA 3F10, 1/5,000 dilution, Roche), and anti-a-
tubulin (DM-1A, 1/5,000 dilution, ICN Biomedicals) antibodies.
Blots were then incubated with horseradish peroxidase (HRP)-
conjugated rabbit anti-rat IgG (A5795, 1/5,000 dilution, Roche)
or donkey anti-mouse IgG (NA1093V, 1/5,000 dilution, GE
Healthcare Bioscience) secondary antibodies respectively, and
immunoreactive proteins were detected by enhanced chemilumi-
nescence (P90720, Millipore).
Tumor Suppressor CHFR
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2.5 mg of wild-type and mutant CHFR pcDNA 3.1+ expression
plasmids, and an empty vector control, were introduced into
HCT116 cells at 70% confluency using the lipofection method
(Lipofectamine 2000, Invitrogen). 2.5 mg of pcDNA 3.1+ vector
harboring FLAG tagged ubiquitin (kindly provided by Dr. K.
Miyazono, Tokyo University) was co-transfected with these
constructs. After 20 h, the cells were treated with 25 mMo f
MG132 (C2211, SIGMA) for 5 h, lysed in HIPS buffer, and
subjected to immunoprecipitation. A 500 mg aliquot of total
protein from the transfected HCT116 cells in 250 ml lysis solution
was mixed with 10 ml of the anti-HA affinity matrix (Roche) pre-
blocked with 2% bovine serum albumin (BSA), and incubated for
4 h with gentle rotation at 4uC. The affinity matrix was washed
with HIPS buffer three times, collected by centrifugation, and the
precipitated proteins were denatured in sample buffer containing
0.1M dithiothreitol (DTT), subjected to 7% SDS-PAGE and
transferred to a PVDF membrane. The transferred proteins were
then incubated with anti-HA (high affinity HA 3F10, 1/5,000
dilution, Roche), or anti-FLAG (monoclonal anti-FLAG M2, 1/
5,000 dilution, Sigma) antibodies. The secondary antibodies used
were as described above for the western blotting procedure.
Intracellular localization of CHFR protein
pcDNA3.1+ expression vectors were introduced into HCT116
cells using the lipofection method, as described earlier. Twenty-
four hours after transfection, the cells were fixed with 4%
paraformaldehyde and then treated with 0.5% Triton X-100
(both in PBS) for 5 min. The cells were preblocked with 1%
normal goat serum (NGS) in PBS for 30 min and incubated with
an anti-HA antibody (high affinity HA 3F10, 1:500 dilution,
Roche) for 1 h at room temperature. An alexa 488-conjugated
goat anti-rat IgG (Invitrogen) was used as the secondary antibody.
A rabbit PML antibody (PM001, 1/300 dilution, MBL) and alexa
594-conjugated goat anti-rabbit IgG (Invitrogen) were used to
detect PML nuclear foci. The cells were counter-stained in each
case with 1mM of Hoechst 33258 (B1155, Sigma) and staining
images were captured using an Axiovart (Zeiss) fluorescence
microscope.
Cell cycle checkpoint analysis
For checkpoint analysis, HCT116 cells were transfected with
IRES2-EGFP expression plasmids harboring wild-type or mutant
CHFR inserts for 5 h and then treated with nocodazole at a
concentration of 200 ng/ml (from a 100 mg/ml stock solution in
dimethyl sulfoxide, Sigma) for 16 h. After the nocodazole
treatment, the cells were fixed in 4% paraformaldehyde/PBS
and the numbers of mitotic cells, which show EGFP fluorescence,
were determined by microscopic examination. The average
percentage of the total EGFP-positive cells that were deemed to
be mitotic was calculated by counting approximately 100 cells
expressing either wild-type or mutant CHFR proteins.
Results
The expression of wild-type and mutant CHFR proteins in
colon cancer cells which lack the endogenous species
Colon cancer cells have lost the endogenous expression of
CHFR, and we thus anticipated that this would be an appropriate
cell system to elucidate the functional domain responsible for the
anti-proliferative effects of CHFR protein by genetic rescue. The
endogenous levels of CHFR mRNA were measured by real-time
RT-PCR in five pancreatic cancer cell lines and six colon cancer
cell lines (Fig. 1C). CHFR transcripts were detectable in each of the
pancreas cell lines tested but three colon cancer derived cell lines,
HCT116, RKO and DLD1, showed no expression of CHFR
mRNA.
The structures of the wild-type and mutant CHFR proteins are
shown in Figure 1A. Expression vectors for these proteins were
introduced transiently into HCT116 cells and subjected to western
blotting with anti-HA antibodies to determine whether the
predicted recombinant CHFR proteins were produced (Fig. 1B).
Positive bands were indeed detected at the expected molecular
weights (wild-type; 72 kDa, DFHA; 57 kDa, DRF; 66 kDa, DCys;
50 kDa), indicating that each CHFR protein product was
efficiently expressed.
The anti-proliferative effects of CHFR are dependent
upon the FHA domain and not the RF or Cys domains
To evaluate the effects of wild-type and mutant CHFR proteins
(DFHA, DRF and DCys) on cell proliferation, recombinant
retroviruses harboring the corresponding cDNAs were introduced
into HCT116 cells. There were no major differences found in the
resulting cell morphologies in each case, as shown in Figure 2A.
Substantial growth suppression was observed following the
introduction of the wild-type CHFR during G418 selection
(Fig. 2A). In addition, whereas the DRF and DCys mutants
showed growth suppressive effects that were almost identical to the
wild-type CHFR, the DFHA protein had minimal inhibitory
effects upon cell proliferation (Fig. 2A).
To more quantitatively evaluate the growth inhibitory effects of
the wild-type and mutant CHFR proteins, a colony formation
assay was carried out using the corresponding retrovirally infected
HCT116 cells under G418 selection (Fig. 2B and C). The
expression of wild-type, DRF and DCys proteins resulted in a
significant decrease in the number of G418-resistant colonies in
this experiment compared with the vector control (p,0.01),
whereas DFHA expressing cells did not show any reduction in
colony number. The same recombinant CHFR retroviruses were
also introduced into RKO cells and similar results were observed
(Fig. 2C).
To verify the titer of our recombinant CHFR retroviruses, the
virus copy numbers in the conditioned supernatant of the PT67
producer cells were measured by real-time PCR. As shown in
Figure 2D, no major differences could be observed in the
retrovirus copy number between the wild-type and mutant CHFR
retrovirus producer cells. We therefore concluded that the growth
suppressive effects of CHFR that we observed in these analyses are
not due to any differences in the titers of the producer cells.
Detection of wild-type and mutant CHFR proteins under
stable expression conditions
During their initial passages, significant growth suppression was
observed in HCT116 cells expressing exogenous wild-type, DRF
and DCys CHFR, as shown in Figures 2A–C. However, this
growth suppression becomes almost undetectable by passage 3.
The protein levels of each of these introduced CHFR products
were thus analyzed in these cells at passage 4 by western blotting.
As shown in Figure 2E, the levels of the wild-type, DRF and DCys
products were remarkably low when compared with DFHA
(Fig. 2E, left panel). The same analysis was undertaken in RKO
cells and produced essentially identical results (Fig. 2E, right
panel). A possible explanation for this phenomenon is that elevated
levels of wild-type, DRF and DCys proteins may cause a
substantial growth disadvantage, and thus cell populations which
express these introduced proteins at low levels undergo positive
selection with passage in culture.
Tumor Suppressor CHFR
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A series of in vivo ubiquitination assays were conducted using
HCT116 cell populations that transiently expressed the wild-type
and mutant CHFR proteins at similar levels (Fig 3, left panel). The
recombinant CHFR and its substrate proteins were immunopre-
cipitated from the corresponding cellular extracts with an anti-HA
antibody and the ubiquitination activity levels were then
monitored by western analysis with anti-FLAG antibodies to
detect high molecular weight bands as described in a previous
study [32]. As shown in the right panel of Figure 3, polyubiqui-
tinated proteins were detectable in cells expressing wild-type and
DFHA proteins but not the DRF and DCys mutants, which is
deemed to be substrates of CHFR. The mobilities of these
immunoprecipitated CHFR proteins were also not altered as a
result of polyubiquitination (Fig. 3, middle panel), indicating that
no self-ubiquitination had occurred in each case. From these
results, we concluded that E3 ligase activity of CHFR requires the
RF and Cys domains, but is unaffected by the deletion of the FHA
domain.
Analysis of the intracellular localization of wild type,
DFHA, DRF and DCys CHFR proteins by
immunofluorescence staining
A previous study has indicated that the FHA domain of the
CHFR protein is essential for its localization in promyelocytic
leukemia (PML) foci within the nucleus [33]. The intracellular
localization of the wild type and mutant CHFR proteins was
detected by immunostaining of HCT116 cells that exogenously
expressed these products. As shown in Figure 4, each of these
Figure 1. Schematic representation of the wild-type, DFHA, DRF and DCys forms of the CHFR protein tagged with HA, and
expression analysis of these proteins in a colon cancer-derived cell line that lacks endogenous CHFR mRNA. (A) The predicted protein
structures of the wild-type, DFHA, DRF and DCys CHFR proteins. N and C indicate the amino and carboxyl terminus, respectively. FHA, forkhead
associated domain; RF, ring finger domain; Cys, cysteine rich domain; HA-tag, hemagglutinin protein tag. (B) The detection of the wild-type, DFHA,
DRF and DCys forms of CHFR proteins transiently expressed in HCT116 cells by western blotting with anti-HA antibodies (upper panel). Cells were
transfected with HA-tagged empty vector (lane 1); wild-type CHFR (lane 2); DFHA (lane 3); DRF (lane 4); or DCys (lane 5). Tubulin was also detected as
a loading control (lower panel). (C) Endogenous CHFR mRNA expression levels detected by real-time PCR in the indicated pancreatic- and colon
cancer-derived cell lines. The relative levels of CHFR mRNA shown are normalized to beta-actin mRNA, the expression level of panc1 was set as 1.0,
and the average values of duplicate experiments were calculated.
doi:10.1371/journal.pone.0001776.g001
Tumor Suppressor CHFR
PLoS ONE | www.plosone.org 4 March 2008 | Volume 3 | Issue 3 | e1776Figure 2. Identification of the functional domain of the CHFR protein that confers its anti-proliferative effects. (A) The growth
appearance of HCT116 cells infected with retroviral vectors expressing the indicated CHFR products. Note that the wild-type CHFR, DRF and DCys
retroviruses suppressed the cell growth of the host cells and this was partially restored in the DFHA expressing cells. There were no differences,
Tumor Suppressor CHFR
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and no differences could be observed. Although the cells were
doubly stained with anti-HA and anti-PML antibodies, a
dominant accumulation of CHFR within the PML nuclear foci
was not evident for either the wild type or mutant proteins. From
these data, we conclude that the CHFR domains analyzed do not
impact upon the intracellular localization of this protein.
The checkpoint function of CHFR requires the FHA
domain only
The functional recovery of the checkpoint function of CHFR
was evaluated also in HCT116 cells after the exogenous
introduction of wild type and mutant CHFR proteins. Since the
transfection efficiency was limited to around 5% for the transient
expression vector, a bicistronic expression vector harboring the
CHFR wild type and mutant inserts was used in these experiments
(Fig. 5A). Since in this case the CHFR and EGFP protein products
are translated from the same mRNA, EGFP fluorescence can be
used as a marker of recombinant CHFR protein expression. To
validate the positive correlation between EGFP expression and
CHFR expression, the percentage of EGFP positive cells that were
immunoreactive also for the anti-HA antibody was determined
microscopically (Fig 5B). Among the 200 EGFP-positive cells that
were counted, 182 (91%) showed positive staining for anti-HA
antibody (Fig. 5B), confirming the usefulness of EGFP as a marker.
As shown in Figure 5C, following nocodazole treatment, the
percentage of EGFP-positive mitotic cells was found to decrease in
conjunction with the expression of the wild type, DRF and DCys
CHFR proteins, compared with the vector control. In contrast, the
expression of the DFHA mutant did not affect the percentage of
mitotic cells. From these data, we conclude that the FHA domain
is essential for the mitotic checkpoint function of CHFR.
Discussion
Our current study has identified the CHFR domains that are
responsible for the anti-proliferative effects of this protein and the
results are summarized in Table 1. We find that both the anti-
proliferative effects and checkpoint function of CHFR require the
FHA domain, whereas the E3 ligase activity of this tumor
suppressor relies on the RF and Cys domains. This suggests that
there is a functional link between the anti-proliferative effects and
checkpoint function of CHFR. Our present analyses also reveal
that the FHA domain is the most important region of CHFR for
its anti-proliferative role, which is in good agreement with several
previous studies. Toyota et al have also reported that the
introduction of a wild-type CHFR expression vector causes the
growth suppression of the host cells, whereas a FHA deletion
mutant did not affect cell growth [19].
Although the data presented by Toyota et al was quite suggestive
of the essential role of FHA in cell growth control, it should be
noted that the cell lines they analyzed (SW480 and T98G)
endogenously express CHFR transcripts (see Fig. 1C for SW480)
[34]. The accurate and quantitative evaluation of the impact of the
DFHA mutant on cell growth is difficult to undertake in the
presence of endogenous protein because of the dominant-negative
properties of this mutant [1]. Interestingly, we detected that the
expression of these mutant CHFR proteins had a completely
different result upon the growth of HeLa cells, which express
r
however, between any of these transfected cells in terms of their morphology. (B) Colony formation assay of HCT116 cells after retroviral infection
with the same CHFR constructs as in (A). (C) Statistical evaluation of the colony formation assay results for HCT116, RKO and HeLa cells expressing the
indicated exogenous proteins. *p,0.01, **p,0.05. (D) Measurements of the recombinant retrovirus copy number in the supernatants of PT67
producer cells by real time PCR. (E) The detection of stably expressed wild-type, DFHA, a DRF and DCys CHFR protein in HCT116 and RKO cells
following infection with the corresponding recombinant retroviruses. Total cellular protein extracts were obtained at the fourth passage. The level of
introduced proteins in the cells that infected with empty vector (lane 1); wild-type CHFR (lane 2); DFHA (lane 3); DRF (lane 4); or DCys (lane 5).
doi:10.1371/journal.pone.0001776.g002
Figure 3. In vivo ubiquitination assay for the wild-type, DFHA, DRF and DCys forms of the CHFR protein. (Left panel) Measurement of the
transient expression levels of both the wild-type and mutant form of CHFR proteins in HCT116 cells by western blotting. The proteins were separated
by 10% SDS-PAGE. (Middle panel) Immunoprecipitation and immunoblotting of proteins with anti-HA antibodies. The proteins were resolved by 7.5%
SDS-PAGE. (Right panel) The detection of FLAG-reactive proteins following immunoprecipitation by HA antibodies. Ubiquitinated proteins are
evident by the presence of high molecular weight bands in lanes 2 and 3, but not in lanes 1, 4 and 5. Cells were cotransfected with FLAG tagged
ubiquitin expression (FLAG-Ubi) vector and either empty vector (lane 1); wild-type CHFR (lane 2); DFHA (lane 3); DRF (lane 4); or DCys (lane 5).
doi:10.1371/journal.pone.0001776.g003
Tumor Suppressor CHFR
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(Fig. 2C). In these experiments, the expression of DFHA induced a
significant increase in colony number whereas the wild-type, DRF
and DCys CHFR species did not show any effects (Fig. 2C, Right
panel). A previous study has indicated that the DFHA mutant of
CHFR acts as a dominant-negative and can disrupt the checkpoint
function of the wild type protein [1]. Hence, we speculated that
the increase in the colony number in HeLa cells by DFHA was
caused by the dominant-negative effects of this mutant upon the
endogenous wild type CHFR protein [1]. The reported existence
of a splicing variant form of CHFR that lacks the FHA domain
and acts in a dominant-negative manner further supports our
contention [19]. It has not yet been reported until this manuscript
to evaluate the effect of FHA domain against cell proliferation
under the two conditions, the existence and non-existence of
endogenous CHFR. We therefore conclude that our current study
is the first report that precisely identifies the functional domain
responsible for the anti-proliferative function of CHFR.
We show from our analysis that the loss of the RF domain and
its associated E3 ligase activity did not disrupt the anti-proliferative
effects of CHFR, suggesting that the E3 ligase activity of this
protein is not essential for its tumor suppressor function. From
previous functional analysis of CHFR knockout mice, however, Yu
et al concluded that the tumor suppressor function of CHFR is
conferred by its E3 ligase activity toward the Aurora A protein, a
predicted oncogenic kinase [21]. There is therefore some
disagreement regarding the precise role of the E3 ligase activity
of CHFR, but possible explanation can be considered. We need to
pay attention to the tissue specificity of CHFR to induce the
degradation of Aurora A. Elevated protein levels of Aurora A are
frequently observed in both human colon and mammary cancers
[25,26], but the inactivation of CHFR is limited to cases of colon
cancer [17,35]. High levels of Aurora A in mammary cancers
cannot therefore be explained by a loss of function of CHFR.
These findings indicate the existence of degradation pathways for
Aurora A that are independent of CHFR [17]. In this regard,
Cdh1 is a strong candidate as an alternative E3 ligase for Aurora A
[36,37]. The exogenous introduction of a dominant-negative form
of Cdh1 was reported to induce elevated levels of Aurora A
protein in HeLa cells [37]. Hence, there may be several molecular
pathways that promote the degradation of Aurora A but that are
tissue- or organ-specific. The protein levels of Aurora A did not
change after the expression of any form of CHFR in HCT116
colon cancer cells in our current experiments (data not shown).
The differences between the findings of this and other studies
might thus be due to the cell-type specificity of the degradation
pathways for Aurora A.
With regards to the E3 ligase activity of CHFR, we found that
the RF and Cys domains are essential. These results are consistent
with previously reported findings, which show that CHFR binds to
its substrates through its Cys domain, and forms a protein complex
with APC/C through its RF domain [21]. Some E3 ligases have
also been reported to have self-ubiquitination activity [38,39], but
we did not detect this in the case of CHFR. In contrast, Kang et al
have reported strong self-ubiquitination activity for CHFR [22].
One possibility to be taken into consideration when evaluating
these discrepancies is the difference of their GST protein tag and
our HA tag. The self ubiquitination activity affected by the protein
tag has reported with MBP protein tag in case of Rma1, EL5 and
Perkin [40–42]. Therefore, further experiments with other protein
tags would be needed to get the conclusion about the self
ubiquitination activity of CHFR protein.
The results of our current study also show that the expression of
CHFR arrests the cell cycle prior to entry into mitosis in the
presence of microtubule depolymerizing reagents, which is
consistent with previous reports [1,19,22,27,28]. A growth
advantage will be conferred upon cells which have lost the
checkpoint machinery that functions under mitotic stress condi-
tions. In agreement with this idea, shRNA knock down of CHFR
recently reported to induce the increased cell proliferation during
the preparation of this manuscript [43]. Since the promoter
methylation of the CHFR gene was detected in non-invasive
adenoma lesions of colon epithelia [44], the associated loss of
the checkpoint function of CHFR in these cells may have a
significant impact upon the early stages of colon carcinogenesis.
To gain further supportive evidence that the FHA domain of
CHFR is important for its growth inhibition properties, we
have recently put a considerable amount of effort into estab-
lishing a conditional expression system for this protein using
the Cre-loxP recombination system [30] to evaluate tumor
formation activity in vivo (e.g. nude mice). Unfortunately, we
have yet to establish an efficient conditional system due to the
toxicity of Cre-expressing adenovirus in HCT116 colon cancer
cells. Although it is not direct evidence, a remarkably high
protein level of the DFHA mutant, compared with that of the wild-
type and other mutant forms of CHFR, suggests that the FHA
domain has an important role in suppressing tumor formation
(Fig. 2E). The FHA domain is expected to work as the binding
motif for phosphorylated proteins. We are currently working on
the experiments to isolate the binding partner of FHA domain of
CHFR protein. There is a possibility that the detail of anti-
Figure 4. Intracellular localization of wild-type and mutant
forms of CHFR proteins detected by fluorescence immuno-
staining. The localization of the wild-type or mutant forms of the CHFR
protein was assessed by the immunoreactivity of an anti-HA antibody
(green signal). PML nuclear foci were detected with an anti-PML
antibody (red signal). The nuclei of HCT116 cells were counterstained
with Hoechst (blue). Merged pictures are shown to highlight the signal
overlap between the Hoechst and anti-HA staining.
doi:10.1371/journal.pone.0001776.g004
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candidates and CHFR. These information will help us to gain
further insights in understanding how a functional loss of this
gene leads to increased cell proliferation during gastrointestinal
carcinogenesis.
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vectors used to express the indicated CHFR products. (B) Validation of the positive correlation between the anti-HA antibody
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Table 1. Summary of the functional properties of wild-type,
DFHA, DRF and DCys CHFR proteins.
Wild type
CHFR DFHA DRF DCys
Anti-proliferative
effects
Yes No Yes Yes
E3 ligase activity Yes Yes No No
Cellular
localization
Nucleus Nucleus Nucleus Nucleus
Checkpoint
function
Yes No Yes Yes
doi:10.1371/journal.pone.0001776.t001
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